I agree that this site is using cookies. You can find further informations here.
X
Strugov, Vladimir
18  results:
Search for persons X
?
1

BTK and PLCG2 remain unmutated in one-third of patients wit..:

Bonfiglio, Silvia ; Sutton, Lesley-Ann ; Ljungström, Viktor...
Blood Advances.  7 (2023)  12 - p. 2794-2806 , 2023
Link: https://doi.org/10.1182/..
 
?
2

First-line treatment of chronic lymphocytic leukemia with i..:

Moreno, Carol ; Greil, Richard ; Demirkan, Fatih...
Haematologica.  107 (2022)  9 - p. 2108-2120 , 2022
Link: https://doi.org/10.3324/..
 
?
3

Five‐year survival follow‐up of a phase III randomised tria..:

Miklos, Udvardy ; Strugov, Vladimir ; Lewerin, Catharina...
British Journal of Haematology.  189 (2020)  4 - p. 689-693 , 2020
Link: https://doi.org/10.1111/..
 
?
4

Impact of MRD Eradication on Survival Outcomes in CLL Patie..:

Timofeeva, Natalia ; Mirolyubova, Iuliya ; Stadnik, Elena...
Clinical Lymphoma Myeloma and Leukemia.  19 (2019)  - p. S273 , 2019
Link: https://doi.org/10.1016/..
 
?
5

Efficacy of Ibrutinib in the Treatment of First Early Relap..:

Timofeeva, Natalia ; Strugov, Vladimir ; Stadnik, Elena...
Clinical Lymphoma Myeloma and Leukemia.  18 (2018)  - p. S216 , 2018
Link: https://doi.org/10.1016/..
 
?
6

Impact of age and comorbidities on the efficacy of FC and F..:

Strugov, Vladimir ; Stadnik, Elena ; Virts, Yulia..
Annals of Hematology.  97 (2018)  11 - p. 2153-2161 , 2018
Link: https://doi.org/10.1007/..
 
?
7

Prospective Evaluation of Safety and Efficacy of BR Regimen..:

Stadnik, Elena ; Strugov, Vladimir ; Andreeva, Tatyana...
Clinical Lymphoma Myeloma and Leukemia.  16 (2016)  - p. S46-S47 , 2016
Link: https://doi.org/10.1016/..
 
?
8

The cost-effectiveness of treatment of relapsed/refractory ..:

Rudakova, Alla V ; Strugov, Vladimir V
Journal of Modern Oncology.  21 (2019)  2 - p. 29-32 , 2019
Link: https://doi.org/10.26442..
 
?
9

BTK and PLCG2 remain unmutated in one-third of patients wit..:

Bonfiglio, Silvia ; Sutton, Lesley-Ann ; Ljungström, Viktor...
Blood Advances, 2473-9529 , 2023, 7:12, s. 2794-2806.  , 2023
Link: http://urn.kb.se/resolve..
 
?
10

BTK and PLCG2 remain unmutated in one-third of patients wit..:

Bonfiglio, Silvia ; Sutton, Lesley-Ann ; Ljungström, Viktor...
info:eu-repo/semantics/altIdentifier/pmid/36696464.  , 2023
Link: https://hdl.handle.net/2..
 
?
11

BTK and PLCG2 remain unmutated in one third of patients wit..:

Bonfiglio, Silvia ; Sutton, Lesley-Ann ; Ljungström, Viktor...
info:eu-repo/semantics/altIdentifier/pmid/36696464.  , 2023
Link: https://hdl.handle.net/2..
 
?
12

BTK and PLCG2 remain unmutated in one-third of patients wit..:

Bonfiglio, Silvia ; Sutton, Lesley-Ann ; Ljungström, Viktor...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279547/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
13

First-line treatment of chronic lymphocytic leukemia with i..:

Dean, James P ; Moreno, Carol ; Greil, Richard...
9ab9c097-5545-4e66-8616-f5313b11d2ff.  , 2022
Link: https://doi.org/10.3324/..
 
?
14

First-line treatment of chronic lymphocytic leukemia with i..:

Moreno, Carol ; Greil, Richard ; Demirkan, Fatih...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425310/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

First-line treatment of chronic lymphocytic leukemia with i..:

Moreno, Carol ; Greil, Richard ; Demirkan, Fatih...
Haematologica.  , 2022
Link: https://ddd.uab.cat/reco..
 
1-15